For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Colostrinin vs DSIP

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

ColostrininDSIP
CategoryNootropic & CognitiveNootropic & Cognitive
Also known asPRP (proline-rich polypeptide), ND, colostrum neuropeptide, CLN, ovine proline-rich polypeptideDelta Sleep Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
EvidenceResearch-stageResearch-stage
Dosing range100mcg–400mcg mcg, sublingual, on a 3 days on / 3 days off cycle100mcg–500mcg mcg, Once daily (evening) or every other day
AdministrationSublingual tablet/dropSubcutaneous injection, Intranasal, Intravenous (clinical studies)
Key side effectsGenerally well-tolerated, Mild GI discomfort, Rare hypersensitivity (relevant for dairy protein sensitivity), Mild fatigue (initial days)Generally well-tolerated, Daytime drowsiness if dosed in morning, Mild headache, Altered dream quality (common)
Cited sources2 references3 references

Key differences

  • Administration: Colostrinin — Sublingual tablet/drop; DSIP — Subcutaneous injection, Intranasal, Intravenous (clinical studies).
  • Frequency: Colostrinin is typically sublingual, on a 3 days on / 3 days off cycle; DSIP is Once daily (evening) or every other day.
  • Research depth: this profile cites 2 sources for Colostrinin vs 3 for DSIP.

How each works

Colostrinin

Colostrinin modulates dendritic cell maturation and shifts cytokine balance toward anti-inflammatory patterns (reduced IL-6, TNF-α; increased IL-10). In neurological models, it reduces amyloid-β aggregation, decreases oxidative stress, and upregulates NGF while modulating the HPA axis stress response. A Polish double-blind trial showed statistically significant cognitive stabilization in mild-to-moderate AD patients over 15 weeks.

DSIP

DSIP does not directly trigger sleep in the simple sense originally proposed — more recent research indicates it modulates the neuroendocrine environment that facilitates sleep. Key findings: it reduces ACTH-driven cortisol elevation under stress, increases GH secretion in some models, and attenuates withdrawal severity in opioid and alcohol dependence (mechanisms unclear). DSIP demonstrates antioxidant effects and has cardioprotective properties in ischemic preconditioning models in animals. Its unique resistance to most peptidases (attributed to its unusual conformation) gives it a relatively long half-life for a nonapeptide.

Read the full Colostrinin profileRead the full DSIP profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.